Tourmaline Bio Inc
TRML20.940USD
-0.820-3.77%
交易中 （美東）報價延遲15分鐘
537.83M總市值
虧損本益比TTM
關於 Tourmaline Bio Inc 公司
Tourmaline Bio, Inc. 是一家後期臨牀生物技術公司。該公司專注於開發變革性藥物，以改善患有改變生活的免疫和炎症疾病患者的生活。該公司的初始候選產品是 TOUR006，這是一種完全人源單克隆抗體，可選擇性結合白細胞介素 6 (IL-6)，這是一種參與許多自身免疫和炎症疾病發病機制的關鍵促炎細胞因子。TOUR006 是一種長效抗 IL-6 抗體，具有與 IL-6 的高結合親和力、長半衰期和低觀察到的免疫原性等特性。該公司還在開發 TOUR006 治療甲狀腺眼病 (TED) 和動脈粥樣硬化性心血管疾病 (ASCVD) 的首兩個適應症，目前正在考慮其他疾病。該公司專注於 TOUR006 的兩條戰略路徑，其中第一條路徑稱爲 FcRn+。其第二條戰略路徑是心血管炎症。
公司簡介
公司代碼TRML
公司名稱Tourmaline Bio Inc
上市日期May 07, 2021
CEODr. Sandeep Kulkarni, M.D.
員工數量74
證券類型Ordinary Share
年結日May 07
公司地址27 West 24th Street, Suite 702
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10010
電話
網址https://www.tourmalinebio.com/
公司代碼TRML
上市日期May 07, 2021
CEODr. Sandeep Kulkarni, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
45.39K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kevin Johnson, Ph.D.
Mr. Kevin Johnson, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Sandeep Kulkarni, M.D.
Dr. Sandeep Kulkarni, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Caley M. Castelein, M.D.
Dr. Caley M. Castelein, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
45.39K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月18日 週日
更新時間: 5月18日 週日
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
9.88%
Avoro Capital Advisors LLC
9.44%
Hydra LLC
6.63%
BlackRock Institutional Trust Company, N.A.
6.23%
TCG Crossover Management, LLC
5.75%
Other
62.07%
持股股東
持股股東
佔比
RA Capital Management, LP
9.88%
Avoro Capital Advisors LLC
9.44%
Hydra LLC
6.63%
BlackRock Institutional Trust Company, N.A.
6.23%
TCG Crossover Management, LLC
5.75%
Other
62.07%
股東類型
持股股東
佔比
Investment Advisor
28.62%
Hedge Fund
23.94%
Investment Advisor/Hedge Fund
20.66%
Venture Capital
14.33%
Corporation
11.58%
Individual Investor
10.35%
Research Firm
2.53%
Bank and Trust
0.30%
Pension Fund
0.16%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
265
28.92M
112.56%
-6.26M
2025Q1
278
29.06M
113.12%
-6.65M
2024Q4
267
27.86M
108.65%
-4.54M
2024Q3
254
27.28M
106.38%
-4.78M
2024Q2
248
27.58M
107.55%
-803.47K
2024Q1
238
26.92M
105.10%
+7.92M
2023Q4
193
17.05M
91.28%
+8.99M
2023Q3
170
3.58M
159.92%
-896.76K
2023Q2
178
3.46M
81.64%
-454.91K
2023Q1
158
3.62M
86.22%
-261.50K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
2.54M
9.88%
--
--
Mar 31, 2025
Avoro Capital Advisors LLC
2.42M
9.44%
+202.78K
+9.13%
Mar 31, 2025
Hydra LLC
1.70M
6.63%
+500.00K
+41.59%
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
1.60M
6.23%
-14.27K
-0.88%
Mar 31, 2025
TCG Crossover Management, LLC
1.48M
5.75%
--
--
Mar 31, 2025
QVT Financial LP
1.47M
5.74%
+762.09K
+107.14%
Mar 31, 2025
Pfizer Inc
1.27M
4.95%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.19M
4.62%
+84.69K
+7.68%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.04M
4.04%
-42.21K
-3.91%
Mar 31, 2025
Castelein (Caley M.)
974.56K
3.79%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
ALPS Medical Breakthroughs ETF
0.28%
iShares Micro-Cap ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.03%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.72%
ALPS Medical Breakthroughs ETF
佔比0.28%
iShares Micro-Cap ETF
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Fidelity Enhanced Small Cap ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
Nuveen ESG Small-Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
公告日期
類型
比率
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
